CRIS Current Research Information System

IORIO, ALFONSO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.612
AS - Asia 2.909
EU - Europa 1.051
Continente sconosciuto - Info sul continente non disponibili 548
SA - Sud America 166
AF - Africa 74
OC - Oceania 7
Totale 8.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.355
VN - Vietnam 997
BD - Bangladesh 556
CN - Cina 466
IT - Italia 463
SG - Singapore 364
GB - Regno Unito 210
HK - Hong Kong 120
CA - Canada 108
DE - Germania 94
BR - Brasile 92
IN - India 76
PH - Filippine 61
JP - Giappone 51
MX - Messico 48
FR - Francia 45
SE - Svezia 44
RU - Federazione Russa 41
TH - Thailandia 40
UA - Ucraina 30
ID - Indonesia 22
KR - Corea 22
CR - Costa Rica 20
JM - Giamaica 20
SA - Arabia Saudita 20
ZA - Sudafrica 20
EE - Estonia 19
NL - Olanda 19
IE - Irlanda 18
AR - Argentina 17
CO - Colombia 17
IQ - Iraq 16
TW - Taiwan 16
TR - Turchia 15
PK - Pakistan 14
VE - Venezuela 13
TG - Togo 12
AT - Austria 11
NI - Nicaragua 11
TT - Trinidad e Tobago 10
EC - Ecuador 9
ES - Italia 9
GT - Guatemala 9
HN - Honduras 9
MY - Malesia 9
PL - Polonia 9
UZ - Uzbekistan 8
AU - Australia 7
FI - Finlandia 7
PT - Portogallo 6
SV - El Salvador 6
CL - Cile 5
EG - Egitto 5
JO - Giordania 5
KE - Kenya 5
MA - Marocco 5
PY - Paraguay 5
SC - Seychelles 5
CI - Costa d'Avorio 4
DZ - Algeria 4
GH - Ghana 4
GR - Grecia 4
IL - Israele 4
KZ - Kazakistan 4
NG - Nigeria 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
BS - Bahamas 3
CH - Svizzera 3
MM - Myanmar 3
PR - Porto Rico 3
RS - Serbia 3
UY - Uruguay 3
BB - Barbados 2
BG - Bulgaria 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
GP - Guadalupe 2
HT - Haiti 2
IR - Iran 2
KW - Kuwait 2
LB - Libano 2
OM - Oman 2
PE - Perù 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
AM - Armenia 1
BE - Belgio 1
BF - Burkina Faso 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
Totale 7.811
Salva come PNG Salva come JPEG
Città #
Ashburn 281
Council Bluffs 251
San Jose 241
Singapore 237
Hanoi 235
Ho Chi Minh City 225
Santa Clara 163
Southend 139
New York 125
Fairfield 113
Los Angeles 98
Hong Kong 97
Dong Ket 72
Houston 68
Chicago 67
Seattle 61
Wilmington 59
Beijing 57
Woodbridge 54
Bologna 52
Dallas 49
Milan 46
Rome 43
Da Nang 42
Haiphong 41
Chandler 40
Princeton 40
Cambridge 38
Buffalo 36
Boardman 34
Tokyo 33
Phoenix 29
Mexico City 28
Ann Arbor 25
Las Vegas 23
San Francisco 23
Atlanta 22
Florence 22
Nanjing 21
Frankfurt am Main 20
Washington 20
Jacksonville 19
Naples 19
Philadelphia 18
San José 18
Bangkok 17
Toronto 17
Westminster 17
Dublin 16
Lauterbourg 16
Padova 16
Berlin 14
Miami 14
Montreal 14
Charlotte 13
Lomé 12
Quezon City 12
Shenyang 12
Columbus 11
Hải Dương 11
Jinan 11
London 11
Managua 11
Queens 11
Shanghai 11
Turin 11
Biên Hòa 10
Can Tho 10
Kingston 10
Des Moines 9
Guatemala City 9
Manila 9
Orem 9
Baltimore 8
Bari 8
Brooklyn 8
Denver 8
Jeddah 8
Palermo 8
Saint Petersburg 8
San Diego 8
Amsterdam 7
Calgary 7
Caracas 7
Chaguanas 7
Lahore 7
Millington 7
Minneapolis 7
Moscow 7
Nanchang 7
Napoli 7
Pasadena 7
São Paulo 7
The Bronx 7
Augusta 6
Falls Church 6
Nuremberg 6
Quận Ba 6
Rio de Janeiro 6
San Salvador 6
Totale 3.979
Salva come PNG Salva come JPEG
Nome #
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis 228
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. 193
Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the hero qualitative study 170
When healthcare professionals express themselves: results overview of the qualitative phase of the HERO initiative 165
Psychological interventions for people with hemophilia 157
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 156
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 149
Psychological interventions for people with hemophilia 145
Risk factors for hospital readmission of elderly patients. 141
AFFECTIVE COGNITIVE AND AFFECTIVE NON-COGNITIVE SOCIAL OBJECTS: A CASE STUDY OF SOCIAL REPRESENTATION OF HEAMOPHILIA FROM THE HERO PROJECT 138
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 138
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 128
D-dimer testing to determine the duration of anticoagulation therapy. 123
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. 122
null 121
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis A patient-level meta-analysis 112
The process of construction and re-construction of the social representation of haemophilia: sensitive issues and affective-cognitive implications 106
Core GRADE 6: Presenting the evidence in summary of findings tables 73
null 73
Risk Factors for the Development of Food Allergy in Infants and Children A Systematic Review and Meta-Analysis 71
Why Core GRADE is needed: Introduction to a new series in the BMJ 70
Attitudes and perceptions of biomedical journal editors in chief towards the use of artificial intelligence chatbots in the scholarly publishing process: a cross-sectional survey 69
GRADE Guidance: Update on Developing Good Practice Statements in Guidelines 67
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes 65
Core GRADE 3: Rating certainty of evidence-assessing inconsistency 64
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project 64
Benchmarking domain-specific pretrained language models to identify the best model for methodological rigor in clinical studies 63
A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A 62
Reporting guideline for chatbot health advice studies: The CHART statement 62
Core GRADE 1: Overview of the Core GRADE approach 62
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025 59
Attitudes and perceptions towards the use of artificial intelligence chatbots in medical journal peer review: A protocol for a large-scale, international cross-sectional survey 59
Non-severe haemophilia: Is it benign? – Insights from the PROBE study 58
Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users 58
Translating clinical questions by physicians into searchable queries: Analytical survey study 57
Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal 55
Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans 55
Core GRADE unpacked: a summary of recent innovations in complementary GRADE methodology 54
Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry‐Based Matched Cohort Study 54
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? 53
Canadian Clinical Experience on Switching From Standard Half‐life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half‐life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada 52
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing 52
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach 51
Core GRADE 2: Choosing the target of certainty rating and assessing imprecision 50
Core GRADE 5: rating certainty of evidence—assessing indirectness 49
florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia 49
von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells 48
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B 48
Country-level prediction of blood type distribution in hemophilia A in support of factor VIII consumption 48
Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey 48
Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method 47
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine 47
null 46
Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study 45
Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins 45
Overall prognosis of preschool autism spectrum disorder diagnoses 45
A mixed-methods survey and focus group study to understand researcher and clinician preferences for a Journal Transparency Tool 45
Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products 43
Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation 42
GRADE concept paper 9: rationale and process for creating a GRADE Ontology 42
Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling 41
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura 41
The World Federation of Hemophilia Annual Global Survey 1999-2018 41
Reported prevalence of von Willebrand disease worldwide in relation to income classification 41
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura 41
How to write a guideline: A proposal for a manuscript template that supports the creation of trustworthy guidelines 40
External qualification of the Web-Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data 40
GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions 40
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A 40
Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature 39
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study 39
Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review 39
GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach 39
The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients 39
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database 38
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia 38
The McMaster Health Information Research Unit: Over a Quarter-Century of Health Informatics Supporting Evidence-Based Medicine 37
Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis 36
Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation 36
Validating the “feasibility, acceptability, cost, and equity” instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implementation 35
Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists 35
Feasibility of Administering the Patient Reported Outcomes, Burdens and Experiences (PROBE) Questionnaire Through the Canadian Bleeding Disorders Registry (CBDR) and Comparison of Data From the Two Sources 35
Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults 34
Von Willebrand Disease: Gaining a global perspective 34
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B 34
GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks 33
GRADE guidance 36: updates to GRADE's approach to addressing inconsistency 33
Deep learning to refine the identification of high-quality clinical research articles from the biomedical literature: Performance evaluation 33
World Federation of Hemophilia Gene Therapy Registry 33
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates 33
Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics 33
Publisher preferences for a journal transparency tool: A modified three-round Delphi study 33
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study 33
Evaluation of the sexual health in people living with hemophilia 32
Health utilities in adults with hemophilia A: A retrospective cohort study 32
Good or best practice statements: Proposal for the operationalisation and implementation of GRADE guidance 32
Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set 31
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A 31
The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO study 31
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS‐Hemo platform 31
Totale 6.297
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.967
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022227 0 0 0 10 30 23 8 24 12 17 45 58
2022/2023201 26 34 8 27 16 18 5 10 28 4 20 5
2023/202477 6 12 7 5 5 11 4 2 7 4 12 2
2024/2025310 19 62 15 20 90 19 17 3 6 9 3 47
2025/20264.782 33 32 53 29 64 36 105 82 1.718 1.100 883 647
2026/20271.869 443 472 594 360 0 0 0 0 0 0 0 0
Totale 8.367